Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Quinazoline derivative as pgk1 (phosphoglycerate kinase 1) activator

A technology of activator and solvate, applied in the field of disease, can solve the problem of lack of apoptosis inhibitor

Active Publication Date: 2012-07-04
北京安塞迩生物科技有限公司
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] So far, there is still a lack of effective inhibitors of apoptosis clinically, and the development of novel anti-apoptotic compounds is used for example in the treatment and / or prevention of sepsis and its complications, as well as stroke sepsis and its complications. Complications are compelling research targets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinazoline derivative as pgk1 (phosphoglycerate kinase 1) activator
  • Quinazoline derivative as pgk1 (phosphoglycerate kinase 1) activator
  • Quinazoline derivative as pgk1 (phosphoglycerate kinase 1) activator

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0146] A, compound preparation example part

[0147] The following preparation examples exemplarily prepare part of the compounds of formula I of the present invention, each compound is represented by Co.1 to Co.32, and Co.33 represents terazosin. In the reaction schemes of the following preparation examples, "reflux" means reflux, and "1-pentanol" means 1-pentanol.

preparation example 1

[0148] Preparation Example 1: Preparation of Co.1

[0149]

[0150] Step 1: Bubble ammonia gas into a 200 mL tetrahydrofuran solution dissolved in compound 1a (50 mmol), and carry out the reaction at 25° C. for 36 hours. A large amount of white solids were precipitated in the system, and the resulting white solids were filtered and washed with tetrahydrofuran to obtain the final product 1f. Yield: 63%.

[0151]

[0152] Step 2: 15 mL of acetic anhydride was added to compound 1f (10 mmol), and the reaction was refluxed for 2 hours. After cooling to room temperature, a large amount of white solids were precipitated in the system. The resulting white solids were filtered and washed with tetrahydrofuran to obtain 1 g of the final product. Yield: 63%.

[0153]

[0154] Step 3: To a solution of 1 g (2 mmol) of 1-pentanol was added under argon atmosphere for 1 h (2 mmol). After the reaction system was refluxed for 4.5 hours, it was placed in an environment of 0-5° C. f...

preparation example 2

[0156] Preparation Example 2: Preparation of Co.2

[0157]

[0158] Step 1: Compound 1b (20 mmol) was added to compound 1a (20 mmol) in 100 mL of methanol solution, and the reaction was carried out at 25° C. for 4 hours. Thin plate chromatography indicated that 1a was completely converted, and 100 mL of diethyl ether was added to the system, mixed evenly, and placed in a -20°C environment for static crystallization. The resulting white solid was recrystallized from petroleum ether / ethyl acetate to obtain the final product 1c. Yield: 41%.

[0159]

[0160] Step 2: To a solution of 1c (2 mmol) in 1-pentanol was added 1d (2 mmol) under argon atmosphere. After the reaction system was refluxed for 4.5 hours, it was placed in an environment of 0-5° C. for static crystallization. The obtained white crystals were washed twice with 10 mL of acetone, and then recrystallized with ether / methanol to obtain the final product 1e, which was compound Co.2. Yield: 62%.

[0161] 1H ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a quinazoline derivative as a pgk1 (phosphoglycerate kinase 1) activator. Specially, the invention relates to application of the compound shown in formula I or pharmaceutically-acceptable salts, solvates, esters and prodrugs thereof in preparing medicines as pgk1 activators, or in preparing medicines for treating and / or preventing hyperglycemia, cerebral thrombosis and complications thereof, wherein the substituents are indicated as in the specification.

Description

technical field [0001] The present invention relates to quinazoline derivatives such as terazosin as pgk1 activators, and their use in treating hyperglycemia, cerebral thrombosis and other diseases. Background technique [0002] Sepsis is the leading cause of death in intensive care units worldwide. Sepsis is thought to be a dysregulation of a complex inflammation (Bone et al., 1996). However, many clinical trials of cytokine or anti-inflammatory specific agents have failed to significantly improve the survival of patients with sepsis, and reconsideration of sepsis treatment strategies is warranted. Antibiotic therapy is an important approach in the treatment of sepsis, although its effectiveness is limited. Basic research shows that inhibition of apoptosis is effective in blocking experimental sepsis. In septic patients, apoptosis of immune cells can further weaken the immune response. In addition, blocking apoptosis has been shown to be an important strategy for the tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/517A61P3/10A61P7/00A61P9/10A61P31/04
Inventor 刘磊许晓椿李笑宇
Owner 北京安塞迩生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com